 |
|
|
| |
Pharmacokinetics, Safety, and Tolerability of Next Generation Direct Acting Antivirals ABT-493 and ABT-530 in Subjects with Renal Impairment
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Matthew P. Kosloski, Sandeep Dutta, Weihan Zhao, David Pugatch, Federico Mensa, Jens Kort, Wei Liu AbbVie Inc., North Chicago, Illinois, United States
EASL: ABT-493 + ABT-530 at EASL - (05/05/16)
|
| |
|
|
|
|
|
